BioTime Inc. priced its previously announced underwritten public offering of 9,615,385 shares at $2.60 apiece.

The company expects to raise $25 million in gross proceeds, which will be used to fund clinical trials, research and development programs, and for general working capital.

The offering is expected to close by Oct. 17 with Raymond James & Associates Inc. acting as the sole book-running manager.

Ladenburg Thalmann & Co. Inc., Chardan and LifeSci Capital LLC are acting as co-managers of the issue while Lake Street Capital Markets is acting as a financial advisor.

The underwriters have an option to purchase up to an additional 1,442,308 of the shares offered in the company.